RAY1225
Sponsors
Guangdong Raynovent Biotech Co., Ltd
Conditions
Basic ScienceHealthyHepatic ImpairmentKidney ImpairmentObeseObesityT2DMT2DM (Type 2 Diabetes Mellitus)
Phase 1
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
CompletedNCT05835752
Start: 2023-05-18End: 2024-03-23Updated: 2026-03-05
A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes
CompletedNCT06577428
Start: 2024-07-30End: 2024-10-08Updated: 2025-03-19
A Study of RAY1225 in Participants With Impaired Liver Function
RecruitingNCT06577415
Start: 2024-08-26End: 2025-11-15Target: 24Updated: 2025-03-19
A Study of RAY1225 in Participants With Impaired Kidney Function
CompletedNCT06613763
Start: 2024-09-11End: 2025-01-20Updated: 2025-03-05
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
Active, not recruitingNCT07362030
Start: 2025-04-14End: 2026-03-30Updated: 2026-01-23
Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants
Not yet recruitingNCT07827027
Start: 2026-09-21End: 2026-12-02Target: 68Updated: 2026-09-18
Phase 2
Phase 3
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
RecruitingNCT06893016
Start: 2025-06-15End: 2026-09-15Target: 640Updated: 2025-07-17
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Not yet recruitingNCT07139535
Start: 2025-08-31End: 2026-12-31Target: 350Updated: 2025-08-24
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
Not yet recruitingNCT07139548
Start: 2025-08-31End: 2026-12-31Target: 600Updated: 2025-08-24